Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia
Vyas P., Daver N., Chao M., Xing G., Renard C., Ramsingh G., Wei AH., Sallman DA.